Jump to content

dydo

Administrators
  • Content Count

    19,559
  • Joined

  • Last visited

  • Days Won

    456

dydo last won the day on June 23

dydo had the most liked content!

Community Reputation

1,577 Excellent

2 Followers

Profile Information

  • Location :
    Canada

Recent Profile Visitors

18,301 profile views
  1. a news just came across https://finance.yahoo.com/news/esperion-announces-publication-journal-american-151224485.html
  2. new article https://seekingalpha.com/article/4355770-esperion-therapeutics-easy-double-maybe-lot presentation https://seekingalpha.com/article/4348809-esperion-therapeutics-espr-investor-presentation-slideshow
  3. Hello, a new conviction pick, Esperion Therapeutics, Inc. (ESPR), brand new medications for the cholesterol, coming on the market in the US and EU. The company has about 30M shares, worth today $1.4B, sales potential of $1B., Price target $150, trades at $53
  4. I think I would agree. Lack of the catalyst, dictates price in this situation. I think $7 is likely. I have folded my position. Own MEIP and SELB.
  5. dydo

    Beyond Solar

    I bought company called MEI Pharma symbol is MEIP, I think it is worth at least $10 but trades around $4.30, good luck.
  6. BABYF release news on production of samples yesterday https://finance.yahoo.com/news/else-nutrition-announces-u-launch-110000651.html
  7. dydo

    Beyond Solar

    Another interesting situation is a company called TAAT Link to a company's website. https://taatusa.com/ It started trading yesterday on CSE. As far as I can tell it does not have US pink sheets symbol. We are talking a grass root start up and entry. I have few shares. It is likely like a BABYF but 6 months ago. Use your own DD.
  8. Hi Marty, Yes, the result was not what was expected. BioMarin’s median level of the factor at year one was 60. At 28 weeks, Pfizer looks to me like that is patient #10, tracking over 60, then you have week 36, patient #11 is not there, leaving it between #7 and #10. 7 is way up there close to 125, while 10 slipped below 50. It appears to me when all hit a year, the 60 achieved by BioMarin will be better because #10 is becoming a median and has fallen under 50.So the only better is hopefully no bleeds. There is also a tremendous amount of variable. Of course, nobody knows what variable was for BMRN. The ALT episodes seem to drop the activity. If there is steroid use, perhaps it can regulate levels of factor avoiding drops, but if one does not need it, since no bleeds or need for replacement, then why bother.The stock sold on unmet expectations, forgetting it is up to Pfizer, to design phase 3, and come up with perhaps even a higher dose and use of steroids to prevent the reduction of factor activity. Also, the lead-in study could answer questions on what characteristics of a patient the treatment would have the most success. I think, since the AFFINE showed up at the end of April and updated in May, Pfizer/Sangamo knew March results already. The decision to start in July was based on the update we saw Thursday. I think this is positive, as Pfizer can manage the design, and they have trial experience and resources surpassing Sangamo. I imagine September all are over 52 weeks; likely December ASH will be the forum to discuss it. We will not know what Pfizer is doing in phase 3; nobody knows what is happening to hemophilia B, so I see no difference here. Do you see anything else come up between now and then? I assumed all trials would be postponed.I also think that ZFN 2.0 is not happening. Ed Rebar was leaving, and I cannot think of any other reason but everyone focusing on Biogen and moving resources away from MPS II. The indication is missing from the corporate deck. I imagine Sangamo is going after diseases with significant prevalence. So cell edit and gene regulation will be the action. I doubt we will see gene therapy either, beyond Fabry. Gene therapy is not ZFN, and the company is ZFN. It makes sense to focus on those. Small genetic diseases are too expensive to address with the budgets of Sangamo.
  9. I guess they got me at hydrogen,
  10. I found this company couple of days ago. Since I am invested in SGMO, I found interesting for them to enable re-dosing of AAV vectors. A huge obstacle as gene therapy is a one time condition. They have also signed a deal with Sobi, huge Swedish biotech company, got $100M and dropped like 30%. So I bought it, two days ago.
  11. Nice move today, I wish we knew more about the company. @ghouston can you provide a view why this is a good investment? Thanks
  12. Expecting news release next week, nicely consolidating around $1.50 US, good base for some stronger runs after the news.
  13. Hi there, I created the forum. If you are interested in providing the content, go ahead.
×
×
  • Create New...